241 related articles for article (PubMed ID: 34033938)
1. Microstructural changes after half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy.
Esen E; Sizmaz S; Demircan N
Photodiagnosis Photodyn Ther; 2021 Sep; 35():102347. PubMed ID: 34033938
[TBL] [Abstract][Full Text] [Related]
2. Long term outer retinal changes in central serous chorioretinopathy submitted to half-dose photodynamic therapy.
Torres-Costa S; Penas S; Cerqueira AR; Brandão E; Carneiro Â; Rocha-Sousa A; Falcão-Reis F
Photodiagnosis Photodyn Ther; 2021 Jun; 34():102235. PubMed ID: 33631379
[TBL] [Abstract][Full Text] [Related]
3. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy.
Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ
Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
Noh SR; Kang MS; Kim K; Kim ES; Yu SY
Korean J Ophthalmol; 2019 Dec; 33(6):506-513. PubMed ID: 31833247
[TBL] [Abstract][Full Text] [Related]
5. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
Matušková V; Vysloužilová D; Uher M
Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
[TBL] [Abstract][Full Text] [Related]
6. Threshold thickness of foveal outer nuclear layer associated with outcomes of photodynamic therapy in central serous chorioretinopathy.
Yu J; Ye X; Li L; Jiang C; Chang Q; Xu G
Eye (Lond); 2022 Oct; 36(10):1884-1889. PubMed ID: 34480115
[TBL] [Abstract][Full Text] [Related]
7. Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy.
Pryds A; Larsen M
Acta Ophthalmol; 2012 Dec; 90(8):738-43. PubMed ID: 21586096
[TBL] [Abstract][Full Text] [Related]
8. The relationship between foveal outer nuclear layer thickness in the active and resolved phases of central serous chorioretinopathy treated with half-dose photodynamic therapy.
Yu J; Lei Y; Chang Q; Xu G; Ye X; Li L; Jiang C
BMC Ophthalmol; 2019 Mar; 19(1):84. PubMed ID: 30922273
[TBL] [Abstract][Full Text] [Related]
9. Relationship between photoreceptor layer changes before half-dose photodynamic therapy and functional and anatomic outcomes in central serous chorioretinopathy.
Yu J; Ye X; Li L; Chang Q; Jiang C
Eye (Lond); 2021 Mar; 35(3):1002-1010. PubMed ID: 32546748
[TBL] [Abstract][Full Text] [Related]
10. CHOROIDAL THICKNESS AFTER FULL-FLUENCE AND HALF-FLUENCE PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Oh BL; Yu HG
Retina; 2015 Aug; 35(8):1555-60. PubMed ID: 25932547
[TBL] [Abstract][Full Text] [Related]
11. Change in subfoveal choroidal thickness in central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy.
Kang NH; Kim YT
Eye (Lond); 2013 Mar; 27(3):387-91. PubMed ID: 23288136
[TBL] [Abstract][Full Text] [Related]
12. Early choriocapillaris changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy evaluated by optical coherence tomography angiography: Preliminary results.
Demircan A; Yesilkaya C; Alkin Z
Photodiagnosis Photodyn Ther; 2018 Mar; 21():375-378. PubMed ID: 29409857
[TBL] [Abstract][Full Text] [Related]
13. Assessment of choroidal topographic changes by swept source optical coherence tomography after photodynamic therapy for central serous chorioretinopathy.
Razavi S; Souied EH; Cavallero E; Weber M; Querques G
Am J Ophthalmol; 2014 Apr; 157(4):852-60. PubMed ID: 24412124
[TBL] [Abstract][Full Text] [Related]
14. Early visual and morphologic changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Alkin Z; Ozkaya A; Agca A; Yazici AT; Demirok A
J Ocul Pharmacol Ther; 2014 May; 30(4):359-65. PubMed ID: 24456481
[TBL] [Abstract][Full Text] [Related]
15. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].
Liu Y; Li L; Xu G; Wang W
Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704
[TBL] [Abstract][Full Text] [Related]
16. Optical coherent tomographic angiographic pattern of the deep choroidal layer and choriocapillaris after photodynamic therapy for central serous chorioretinopathy.
Chan SY; Pan CT; Wang Q; Shi XH; Jonas JB; Wei WB
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1365-1372. PubMed ID: 31037490
[TBL] [Abstract][Full Text] [Related]
17. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
[TBL] [Abstract][Full Text] [Related]
18. [Choroidal thickness after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy].
Zeng J; Yan YY; Ding XY; Liu R; Li JQ
Zhonghua Yan Ke Za Zhi; 2013 Jun; 49(6):490-4. PubMed ID: 24119960
[TBL] [Abstract][Full Text] [Related]
19. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
Maruko I; Iida T; Sugano Y; Ojima A; Ogasawara M; Spaide RF
Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Retinochoroidal Vascular and Structural Changes after Half-Dose Photodynamic Therapy versus Half-Fluence Photodynamic Therapy Based on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy.
Karasu B; Akbas YB; Aykut A; Celebi ARC
Ophthalmologica; 2022; 245(4):323-334. PubMed ID: 35249031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
